Figure 1.
The therapeutic effects of WKYMVm in an experimental ulcerative colitis model. Established colitis was induced using 3% dextran sodium sulfate (DSS) in water. WKYMVm (8 mg kg−1) was subcutaneously administered six times (at 0, 12, 24, 36, 48 and 60 h) after establishing the DSS model in the absence (a–c) or presence of cyclosporine H (CsH) (4 mg kg−1) or WRWWWW (WRW4) (4 mg kg−1) (d–f). Body weights (a, d), stool scores (b, e) and bleeding scores (c, f) were measured daily. The data obtained at day 7 are shown in (d–f). The data are expressed as the mean±s.e.m. **P<0.01, ***P<0.001 compared with control. #P<0.05 compared with DSS alone. Sample size: n=8 mice per group (a–c) or n=5 mice per group (d–f).